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The N-terminal hydrophilic ectodomain of the GL envelope glycoprotein of equine arteritis virus (EAV) contains neutraliza-
tion determinants of the virus. We developed a panel of 17 neutralizing murine monoclonal antibodies (MAbs) to further
characterize the neutralization determinants of EAV. Included were 6 MAbs previously raised against a laboratory strain
(EAVUCD) of the original Bucyrus strain of EAV, as well as 11 additional MAbs that were raised against a neutralization-
resistant variant [escape mutant (EM)] virus (EM6D10) that was derived from EAVUCD. All MAbs raised against EAVUCD
and 4 of the MAbs raised against EM6D10 (2B3, 5F8, 8D4, and 10B4) reacted with the corresponding GL envelope glycoprotein
in a Western immunoblotting assay, whereas the remaining 7 MAbs raised against EM6D10 did not react with any viral
protein in the immunoblotting assay but competitively inhibited the binding of MAbs 2B3, 5F8, 8D4, and 10B4, indicating
that they also recognize epitopes on the GL protein. A panel of 18 EM viruses raised to the MAb panel, 19 field isolates of
EAV from North America and Europe, the modified-live virus vaccine (ARVAC), and 3 other laboratory strains of EAV were
characterized by microneutralization assay with the panel of neutralizing MAbs and polyclonal rabbit and horse antisera.
Comparative analysis of the nucleotide sequences of ORF5 and the deduced amino acid sequences of the GL protein of
individual EM viruses and field isolates of EAV identified four distinct neutralization sites. These sites include amino acids
49 (site A), 61 (site B), 67 through 90 (site C), and 99 through 106 (site D). With the notable exception of site A, the sites
were all located in the V1 variable region (amino acids 61–121) within the second half of the N-terminal hydrophilic
ectodomain of the GL protein. Site D includes several overlapping linear epitopes which appear to interact with amino acids
in the other three sites to form conformationally dependent epitopes. Amino acid substitutions within any of these four
sites can alter the neutralization phenotype of individual strains of EAV. q 1997 Academic Press
INTRODUCTION on Taxonomy of Viruses (ICTV) placed these four viruses
in an independent family Arteriviridae containing a single
Equine arteritis virus (EAV) is distributed throughout genus Arterivirus (Murphy, 1997). The committee also
the world and causes periodic outbreaks of equine viral created an order Nidovirales that includes the families
arteritis (EVA) in horses (Akashi et al., 1975; Moraillon Arteriviridae and Coronaviridae.
and Moraillon, 1978; McCollum and Bryans, 1973; Hun- The EAV genome consist of 12,704 nucleotides and
tington et al., 1990; Camm and Thursby-Pelham, 1993; includes at least eight open reading frames (ORFs: 1a,
Nosetto et al., 1984). EAV infection can cause pneumonia 1b, 2, 3, 4, 5, 6, and 7; den Boon et al., 1991). The ORFs
in very young foals, abortion in pregnant mares, and per- 1a and 1b are approximately 9.5 kb in length, are located
sistent infection of stallions (Carman et al., 1988; Timoney at the 5 * end of the genome, and encode the viral repli-
et al., 1986, 1987, 1992; Doll et al., 1957a,b; Golnik et al., case. The ORFs 2 to 7 are located within 2.9 kb at the
1981). EAV is an enveloped, positive-stranded RNA virus 3 * end of the genome and during replication a nested
(Horzinek, 1981), and it recently has been demonstrated set of six 3 *-coterminal viral subgenomic mRNAs are
that EAV resembles lactate dehydrogenase-elevating vi- produced (den Boon et al., 1991 and de Vries et al., 1990).
rus, porcine reproductive and respiratory syndrome virus, The ORFs 2, 5, and 6 encode known viral membrane
and simian hemorrhagic fever virus in its genome organi- proteins; ORF7 encodes the 14-kDa nucleocapsid protein
zation, replication strategy, and tropism for macrophages (N; de Vries et al., 1992). The ORFs 2 and 5, respectively,
(den Boon et al., 1991; Meulenberg et al., 1994). Because encode 25- (GS) and 30-kDa (GL) envelope glycoproteins,
of their similarities, in 1996 the International Committee whereas ORF6 encodes a 17-kDa unglycosylated enve-
lope protein (M).
Genomic variation among field strains of EAV has been1 To whom correspondence and reprint requests should be ad-
dressed. demonstrated by RNase T1 oligonucleotide fingerprinting
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(Murphy et al., 1988, 1992) and sequence analysis of ble for differences in neutralization phenotype of the vari-
ous viruses.ORFs 6 and 7 (Chirnside et al., 1994; Sugita et al., 1994).
We recently have reported the genetic variation and phy-
logenetic analysis of ORF2 and ORF5 of a large number MATERIALS AND METHODS
of field isolates and laboratory strains of EAV, and the
Cells and virusesmodified-live vaccine virus (Balasuriya et al., 1995b;
Hedges et al., 1996). Comparison of the deduced amino Rabbit kidney 13 (RK-13; ATCC CCL 37) cells were
acid sequences of the GL protein of these viruses identi- maintained in Dulbecco’s modified Eagle’s medium
fied a putative signal sequence [S (aa 1–18)], three dis- (DMEM) supplemented with 10% heat-inactivated calf se-
tinct variable regions [V1 (aa 61–121), V2 (141–178), V3 rum (CS; Hyclone Laboratories, Inc., Logan, UT), 100 IU
(202–222)], and four conserved regions [C1 (aa 19–60), of Penicillin, and 100 mg of Streptomycin per milliliter.
C2 (122–140), C3 (179–201), and C4 (223–255)]. Murine myeloma P3X63Ag8.653 cells were obtained from
Although there apparently is only one serotype of EAV, the American Type Culture Collection (Bethesda, MD;
there appears to be considerable antigenic variation Kearney et al., 1979) and cultured in RPMI 1640 (Bio-
among field strains based on their neutralization by Whittaker, Walkersville, MD) supplemented with 10% CS,
monoclonal and polyclonal antisera, and the requirement 5% hybridoma growth factor from murine P388D1 cells
for complement for effective neutralization of some (Bazin and Lemieux, 1987), 0.1% 10 mM nonessential
strains (McCollum and Swerczek, 1978; Golnik et al., amino acids, and 1% 100 mM sodium pyruvate (Sigma,
1986; Murphy et al., 1988; Fukunaga et al., 1993, 1994; St. Louis, MO).
Fukunaga and McCollum, 1977; Glaser et al., 1995, The phenotypic variation of 22 laboratory strains [in-
Kondo et al., 1994; Westcott et al., 1995). In addition, cluding EAVUCD, EAV X2.4, EAVCVDLS, EAVATCC
geographically and temporally distinct EAV isolates differ (ATCC VR-796) and 18 EM viruses; see below], the modi-
in the severity of the clinical disease they induce and in fied live virus vaccine (ARVAC, Fort Dodge Laboratories,
their abortigenic potential (McCollum and Swerczek, IA), and 19 field strains of EAV was determined. The
1978; Timoney and McCollum, 1993). The GL protein en- field isolates were collected over a 40-year period from
coded by ORF5 expresses the known neutralization de- throughout the United States (VBS53, PA76, KY63, KY77,
terminants of EAV (Chirnside et al., 1995; Glaser et al., KY84, KY93, AZ87, NE88, NE89, MT89, MI93, IL93AB, and
1995; Balasuriya et al., 1993, 1995a; Deregt et al., 1994, IL93TB), western Canada (CAN86), and Europe (SWZ64,
Westcott et al., 1995). We previously have shown that AUT68, PLD76, and ITA92). Passage histories of these
amino acids 99 through 104 of the GL envelope glycopro- viruses have been previously reported (Balasuriya et al.,
tein are critical for virus neutralization (Balasuriya et al., 1995b). The isolation and genotypic characterization of
1995a). In addition, we have demonstrated that the major- two strains of EAV isolated from the semen of two persis-
ity of amino acid substitutions in the GL protein of field tently infected stallions in California (CA95G and CA95I)
isolates of EAV are localized to the V1 (aa 61–121) vari- will be published elsewhere (Balasuriya et al., 1997b).
able region (Balasuriya et al., 1995b). We predict, there- All EM viruses ultimately were derived from our proto-
fore, that these amino acid changes in the V1 region of type strain of EAV (EAVUCD), which originally was de-
the GL protein would alter the neutralization determinants rived from the Bucyrus strain of EAV that was obtained
of EAV, perhaps leading to antigenic variation among from the National Veterinary Services Laboratory, Ames,
EAV strains. IA (EAV-NVSL; this virus was generously provided by
The objectives of this study were to further character- Dr. A. Castro, California Veterinary Diagnostic Laboratory
ize the neutralization determinants of EAV and to charac- System, Davis, CA). The passage history of the EAVUCD
terize variation in the neutralization phenotype of a large prototype has been previously reported (Balasuriya et al.,
panel of field isolates and laboratory strains of EAV. Char- 1995a,b).
acterization of the neutralization determinants of EAV is
prerequisite to the logical development of improved vac- Polyclonal anti-sera
cines and diagnostic methodologies for EAV. To achieve
these objectives, large panels of neutralizing MAbs and Anti-EAV equine sera from a horse inoculated with the
Bucyrus strain of EAV (EqKy; Balasuriya et al., 1993) andneutralization-resistant variant [escape mutant (EM)] vi-
ruses were developed. The genotypic and phenotypic three persistently infected stallions from California (G, I,
and J) were used to phenotypically characterize the vari-characterization of these EM viruses identified a number
of conformational and nonconformational neutralization ous strains of EAV. Anti-EAV hyperimmune rabbit serum
(No. 5595) was produced by immunizing New Zealanddeterminants of EAV. The MAbs were then used for phe-
notypic characterization of field isolates of EAV, and com- white rabbits with the EAVUCD laboratory strain. Briefly,
the supernatant from EAVUCD-infected RK-13 cells wasparison of data obtained from these studies with that
from the EM viruses showed that antigenic variation in ultracentrifuged at 120,000 g for 4 hr at 47. The virus
pellet was resuspended in NET buffer (150 mM NaCl, 5the V1 region of the GL protein principally was responsi-
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mM EDTA, and 50 mM Tris, pH 7.5) and the rabbits were et al., 1993, 1995a). EAVUCD and EM6D10 were used as
antigens for screening and characterization of the MAbs.initially immunized by subcutaneous (S/C) injection of 1:2
emulsion of virus in Freund’s complete adjuvant. Rabbits
Competitive ELISA (cELISA)were subsequently boosted three times (2 weeks apart)
by S/C injection of the same antigen in Freund’s incom- The MAbs raised against EM6D10 were further char-
plete adjuvant. Serum from an uninfected horse (EqDG) acterized by cELISA to demonstrate that neutralizing epi-
and preinoculation rabbit serum were used as the nega- topes recognized by MAbs in the panel are located in
tive controls. All sera were heat inactivated (567 for 30 the GL major envelope glycoprotein of EAV, as previously
min) and stored at 0207. described (Balasuriya et al., 1993). ELISA plates were
coated with cesium chloride (CsCl) gradient-purified
Generation and characterization of monoclonal EM6D10 at a concentration of 30 mg/ml in coating buffer
antibodies (MAbs) (150 mM sodium chloride, 70 mM sodium phosphate
buffer, 1% lactose, pH 8.0; Balasuriya et al., 1993). LogThe generation and characterization of six neutralizing
dilutions (50 to 50,000 ng/ml) of unbiotinylated inhibitoryMAbs to the prototype strain of EAVUCD (5G11, 6D10,
MAb and biotinylated test MAb (2,000 ng/ml) were re-7E5, 9F2, 10F11, and 10H4) used in this study were de-
acted to determine the ability of the unbiotinylated inhibi-scribed previously (Balasuriya et al., 1993, 1995a). A sec-
tory MAb to block the binding of each biotinylated MAb.ond panel of 11 neutralizing MAbs was generated by
Bound biotinylated MAb was detected with Avidin-HRPimmunizing mice with a neutralization-resistant variant
(Zymed, San Francisco, CA) and O-Phenylenediamine(EM) virus that was selected by propagating EAVUCD in
[1,2-Benzene diamine] (OPD; Sigma, St Louis, MO) en-the presence of MAb 6D10 (EM6D10; Balasuriya et al.,
zyme-substrate system. Inhibition of binding of the biotin-1995a). MAbs to EM6D10 were produced according to
ylated MAb by each unbiotinylated MAb was then calcu-standard protocols similar to those previously described
lated and expressed as a percentage. Inhibition that was(Heidner et al., 1988; Balasuriya et al., 1993). Briefly, mice
⁄50% at 50,000 ng/ml of inhibitory IgG was regarded aswere initially immunized by intravenous (I/V) injection of
positive.gradient purified EM6D10 (Balasuriya et al., 1995a), and
subsequently boosted three times (10–14 days apart) by
Phenotypic characterization of laboratory strains andintraperitoneal (I/P) injection of the same antigen (1:2
field isolates of EAVemulsion in Freund’s complete or incomplete adjuvant).
The mice were I/V administered with virus 3 days prior Antibody titers of MAbs (ascitic fluid) and polyclonal
to fusion. Fusion of splenic lymphocytes with cells from antiserum were determined by microneutralization assay
the P3X63Ag8.653 myeloma cell line (Kearney et al., using EM6D10 as the challenge virus, in the absence
1979) was done in the presence of polyethylene glycol of complement (Balasuriya et al., 1993). Heat-inactivated
in RPMI medium. Hybridomas secreting EAV-specific sera and ascitic fluid were diluted twofold in MEM. The
neutralizing MAbs were identified by microneutralization initial dilution of serum was 1:16 and 1:100 for ascitic
assay and cloned three times by limiting dilution in 96- fluid. Diluted sera or ascitic fluid was mixed with approxi-
well plates (Lietzke and Unsicker, 1985). mately 500 TCID50 of EM6D10 for 30 min at 377. RK-13
Ascitic fluid was produced by I/P administration of cells then were added and cultures were incubated at 377
each hybridoma into BALB/c mice. Mice were primed for 60–72 hr until cytopathic effect had fully developed
by two I/P injections of 0.5 ml of pristane (2, 6, 10, 14- in control wells. Antibody titers were recorded as the
tetramethyl pentadecane; Sigma, St. Louis, MO) at a 5- reciprocal of the highest final dilution that provided at
week interval prior to inoculation of hybridoma cells. least 50% protection of the monolayer.
Immunoglobulin isotyping was done by ELISA using a
commercial kit (Sigma, St. Louis, MO). Purified immuno- Generation of neutralization-resistant variant viruses
globulin G (IgG) from each MAb and the polyclonal to MAbs
equine antisera was prepared with ABX 40-mm ion ex-
The production and characterization of seven EM vi-
change resin (J. T. Baker Inc., Phillipsburg, NJ). Each
ruses to the panel of six MAbs raised to EAVUCD has
MAb was biotinylated according to a method previously
been previously described (EM5G11, EM6D10, EM7E5,
described (Liddell and Cryer, 1991; Goding, 1986). All
EM9F2, EM10F11, EM10H4, and DEM6D10/10H4; Bal-
neutralizing MAbs were further characterized by both
asuriya et al., 1995a). The polyclonal equine anti-EAV
Western immunoblot and competitive binding [competi-
sera neutralized these EM viruses and their parental vi-
tive ELISA (cELISA)] assays.
rus (EAVUCD) to equivalent titers, indicating that other
neutralization sites exist on the GL protein. In the presentWestern immunoblotting assay
study, therefore, an additional panel of 11 neutralizing
MAbs (designated 1H7, 1H9, 2B3, 3F4, 5E8, 5F8, 6A2,The Western immunoblotting assay of EAV proteins
was done essentially as described previously (Balasuriya 7C5, 7D4, 8D4, and 10B4) raised against EM6D10 was
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TABLE 1used to select 13 ‘‘double’’ EM viruses (DEMs). Briefly,
EM 6D10 was incubated with each of the neutralizing Characteristics of MAbs to EM 6D10
MAbs for 30 min at 377, then placed onto confluent mono-
Monoclonal Neutralizationlayers of RK-13 cells and incubated at 377 for 24 hr. The
antibody Isotype titerainoculated cultures were lysed by freezing at 0707, and
the lysates were subjected to two further blind passages
1H7 IgG1 3200
in the presence of the selecting MAb. After the third 1H9 IgG2B 6400
passage, 10-fold dilutions of the lysate were incubated 2B3 IgG2A 6400
3F4 IgG2A 12800with the selecting MAb for 30 min, inoculated onto RK-
5E8 IgM 640013 cells, and then overlayed with agarose. The inoculated
5F8 IgG2A 6400cultures were incubated at 377 for an additional 2–3 days
6A2 IgG2A 12800
when a second overlay containing neutral red dye was 7C5 IgG3 12800
added. Monolayers were viewed regularly until individual 7D4 IgM 1600
8D4 IgG3 800plaques were readily visualized. Virus from selected
10B4 IgG2A 6400plaques was aspirated and again plaque-picked in the
presence of the selecting MAb, and a stock of virus was a Neutralization titers are expressed as the inverse of the antibody
then propagated in RK-13 cells. Each virus was named dilution providing 50% protection of RK-13 cell monolayers against 500
after the MAb used for its selection (DEM 1H7. 13, 1H9. TCID50 of virus.
7, 2B3. 20, 2B3. 25, 3F4. 8, 5E8. 22, 5F8. 6, 6A2. 12, 7C5.
17, 7D4. 30, 8D4. 18, 10B4. 3, and 10B4. 9). For some
MAbs, more than one DEM virus was selected (i.e., DEM sion products during 25 cycles consisting of 30 sec dena-
2B3. 20, 2B3. 25, 10B4. 3, and 10B4. 9). EM6D10 virus turation at 967, 15 sec annealing at 507 and 4 min exten-
was passaged in the absence of MAb and plaque picked sion at 607. Sequence data was collected and edited with
in the same manner and designated EAV X2.4 for use as an ABI 377 Automatic Sequencer (Applied Biosystems,
a control. Alameda, CA) according to the manufacturer’s instruc-
tions. Nucleotide sequences were translated into the re-
spective amino acid sequences with a Power MacintoshPCR amplification and sequencing of ORF5
8100/100AV computer using HIBIO MacDNASIS Pro Ver-
Total RNA was extracted from virus-infected RK-13 cells sion 3.5 software (Hitachi Software Engineering Co., Ltd.,
using guanidinium thiocyanate and phenol (RNAzol B; Tel- San Bruno, CA).
Test, Inc., Friendswood, TX) according to the manufactur-
ers protocol and as previously described (Balasuriya et al.,
1995a,b). The published sequence of a laboratory strain of RESULTS
the original Bucyrus virus (EAVUtr; den Boon et al., 1991,
Generation and characterization of monoclonalGenBank Accession No. X53459) was used to design syn-
antibodiesthetic oligodeoxynucleotide primers (National Biosciences
Inc., St. Paul, MN) for amplification and sequencing of
The production and characterization of the six neu-ORF5 and flanking portions of ORF4 and ORF6 from each
tralizing MAbs to EAVUCD has been previously de-EM virus, as previously described (Balasuriya et al.,
scribed (Balasuriya et al., 1993, 1995a). Eleven additional1995a,b); positive primers: 11,023–11,042, 11,255–11,276,
hybridomas which produced EM6D10-specific antibod-11,540–11,561; negative primers: 11,978–11,998, 11,940–
ies were identified by microneutralization and Western11,961, 11,674–11,695, 11,425–11,445, 11,218–11,239).
immunoblotting assays using EM6D10 as antigen. TheThe negative primer 11,978–11,998 was used to reverse
immunoglobulin isotype and neutralization titer of eachtranscribe the positive-sense viral RNA to cDNA. PCR am-
MAb is listed in Table 1. Four of the neutralizing MAbsplification was then carried out with the 11,023–11,042
(2B3, 5F8, 8D4, and 10B4) strongly reacted with the GLand 11,978–11,998 primers. The GeneAmp RNA PCR kit
protein in a Western immunoblotting assay (Fig. 1, repre-(Perkin–Elmer Corp., Foster City, CA) was used for re-
sentative examples are in lanes 5 and 7), whereas sevenverse transcription of the viral RNA to cDNA and for subse-
of the neutralizing MAbs did not react with any viral pro-quent amplification of the cDNA (Balasuriya et al., 1995a).
tein in the immunoblotting assay (Fig. 1, representativeBoth positive and negative strands of cDNA from each
examples are in lanes 6 and 9) and their protein specific-amplicon were sequenced with at least three primers per
ity was defined by two way cELISA with biotinylated andstrand using the PRISM Ready Reaction DyeDeoxy Termi-
unbiotinylated MAbs. These seven MAbs strongly inhib-nator (Applied Biosystems, Alameda, CA) cycle sequenc-
ited (⁄50% inhibition) the binding of MAbs 2B3, 5F8, 8D4,ing kit. Approximately 150–200 ng cDNA and 10 pmol
and 10B4, indicating that they recognize conformationallyprimer were used in each reaction. Fluorescently labeled
dideoxynucleotides were directly incorporated into exten- dependent epitopes on the GL protein (data not shown).
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FIG. 1. Representative examples of immunoblotting of the prototype (EAVUCD) and neutralization-resistant (EM6D10) viruses with MAbs and
polyclonal equine antisera. The antigen present in each lane is indicated immediately beneath the lane number, and the specific blotting antibody
(IgG or tissue culture fluid) is identified below the lane. MAb 7B9 specific for the nucleocapsid protein of EAV and normal equine serum are used
as controls (Balasuriya, 1997a). The Mr of significant EAV proteins are indicated on the right, and the specific structural proteins identified by the
MAbs and polyclonal equine serum are indicated on the left.
Neutralization phenotype of neutralization-resistant tralized by MAbs 3F4, 5E8, 7D4, and 10B4, to titers that
varied from 400 to 12,800. These data, together withvariant viruses
those of the competitive binding studies, suggest that
A panel of DEM viruses was derived from EM6D10
the MAbs recognize multiple linear and conformationally
using the MAb panel. The neutralization phenotype of
dependent neutralization determinants on the GL enve-each virus was characterized by microneutralization
lope glycoprotein of EAV.
assay using the MAb panel and polyclonal anti-EAV
Anti-EAV serum derived from horses that were naturally
equine and rabbit sera. A fourfold or greater difference
infected with EAV also neutralized the EM viruses to vari-
in neutralization titer between viruses was regarded as
able titers (16 to 512; Table 2). As compared to the other
a significant change in neutralization phenotype (Table
EM viruses, however, the DEMs 3F4. 8 and 10B4. 3 were
2). All DEMs were not neutralized by the MAb used for
neutralized to low titers by equine anti-EAV sera (16 to
their selection. With the notable exception of MAb 1H7,
64). Equine anti-EAV serum (EqKy) derived from a horse
DEMs 3F4. 8, and 10B4. 3 were not consistently neutral-
experimentally inoculated with the original Bucyrus virus
ized by any of the MAbs in the panel. With the exception
neutralized all the viruses to titers of 128 to 512. Polyclonal
of DEMs 1H7. 13, 1H9. 7, 5E8. 22, 6A2. 12, 7D4. 30, and
anti-EAV rabbit serum neutralized most EM viruses to titers
10B4. 9, which were neutralized by MAb 10H4 to titers
that ranged from 64 to 256 (Table 2), but the rabbit antise-
ranging from 1,600 to 12,800, the DEMs were not neutral-
rum failed to neutralize either DEM 3F4. 8 or 10B4. 3.
ized by any of the MAbs raised against EAVUCD (MAbs
5G11, 6D10, 7E5, 9F2, 10F11, and 10H4). All the MAbs Sequence alterations in ORF5 and amino acid
raised against EM6D10 neutralized DEM 1H7. 13 except substitutions in the GL protein that confer resistanceMAb 1H9, and the DEM 1H9. 7 was neutralized by all of EM viruses to neutralization
MAbs raised against EM6D10 except MAbs 6A2 and
7D4. The DEMs 2B3. 20, 2B3. 25, and 8D4. 18 had a ORF5 from each DEM virus was sequenced in its
entirety and compared to that of EAVUCD. EAVUCD issimilar neutralization phenotype; however, 8D4. 18 was
neutralized to a lower titer (800) by MAb 6A2 as com- the parent virus of EM6D10 (Balasuriya et al., 1995a)
and all the DEMs used in this study were derived frompared to DEMs to 2B3. 20 and 2B3. 25 (12,800). DEMs
5F8. 6 and 10B4. 9 had a similar neutralization phenotype; EM 6D10. The nucleotide and amino acid substitutions
in each DEM virus are indicated in Table 4 and bothhowever, DEM 5F8. 6 escaped neutralization by MAb
10H4, whereas DEM 10B4. 9 was neutralized by the the nucleotide and the amino acid sequences of DEMs
are numbered according to the published sequence ofsame MAb to a significant titer (1600). DEMs 6A2. 12
and 7D4. 30 had a similar neutralization phenotype, but EAVUtr (den Boon et al., 1991) for consistency. All the
DEMs consistently maintained the nucleotide changeneutralization titers differed by at least fourfold with
MAbs 1H7, 3F4, 5F8, and 7C5. DEM 5E8. 22 was neutral- at position 11,423 of ORF5 that is present in EM6D10.
The nucleotide at position 11,423 was changed to Gized by all but 2 MAbs (1H9 and 8D4) to variable titers
ranging from 800 to 12,800. DEM 7C5. 17 was only neu- (T r G as compared to EAVUCD or C r G as compared
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to the EM 6D10) in DEM 2B3. 25. The nucleotide at
position 11,424 of this virus also was changed from A
to T. Both changes produce a codon change (TAC r
GTC) resulting in a tyrosine to valine substitution (histi-
dine to valine as compared to EM 6D10) at position 99
of DEM 2B3.25. Another DEM (2B3. 20) to the same
antibody (MAb 2B3) had only the latter nucleotide
change (A r T), which resulted in a tyrosine to leucine
(histidine to leucine as compared to EM 6D10) at posi-
tion 99. Similarly, the nucleotide change at 11,424 of
three other DEMs (5F8. 6, 8D4. 18, and 10B4. 9) re-
sulted in proline and leucine substitutions at position
99 (Table 4 and Fig. 2). All such changes at position
99 were from uncharged polar (basic as compared to
EM 6D10) to nonpolar amino acids (leucine, valine, or
proline) and change the neutralization phenotype of
DEM 2B3. 30, 2B3, 25, 5F8. 6, 8D4. 18, and 10B4. 9.
These findings strongly suggest that MAbs 2B3, 5F8,
8D4, and 10B4 recognized the same or overlapping
epitopes at position 99. The fact that these four MAbs
bind the GL protein of EM6D10 in a Western immu-
noblotting assay further suggests that they recognize
a linear epitope that centers on amino acid 99 of the
GL protein.
DEMs 1H9. 7, 6A2. 12, and 7D4. 30 had the same
nucleotide change at position 11,334 and hence the
same amino acid substitution (leucine to proline) at posi-
tion 69. Except for DEM 5F8.6 and 10B4.9, all the other
DEMs were not neutralized by MAb 1H9. This suggests
that the epitope recognized by 1H9 is conformational and
formed by amino acid 69 and the four amino acids from
99 to 102. MAb 6A2 did not neutralize DEM 7C5. 17,
which had a leucine to glutamine substitution at position
102, suggesting that the epitope recognized by MAb 6A2
is conformational and formed by amino acids 69 and 102.
MAb 7D4 neutralized all the DEMs that had amino acid
substitutions at positions 99 and 102, indicating that it
recognizes a distinct but overlapping conformational epi-
tope. In contrast to MAb 7D4, the MAbs 1H9 and 6A2 do
not neutralize DEM 6D10/10H4, which has a phenylala-
nine to serine substitution at position 103. In addition
DEMs 1H9. 7, 6A2. 12, and 7D4. 30 were also neutralized
by MAb 10H4, which recognizes a linear epitope at amino
acids 102 and 103 (Balasuriya et al., 1995a; Fig. 2). Thus,
MAbs 1H9, 6A2, and 7D4 most likely identify the same or
overlapping conformational epitope(s) formed by amino
acids 69 and 99 to 102.
The nucleotide change at position 11,433 of DEM 7C5.
17 resulted in a leucine to glutamine substitution at posi-
tion 102. This change rendered the virus resistant to
neutralization by MAbs 1H7, 1H9, 2B3, 5F8, 6A2, 7C5,
and 8D4, but not to MAbs 3F4, 5E8, 7D4, and 10B4, which
neutralize the virus to a titer of 400 to 12,800. These
results suggest that the amino acid substitution at posi-
tion 102 can affect both conformational and nonconfor-
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FIG. 2. Aligned deduced amino acid sequence of the critical neutralization region of the GL proteins of laboratory and field stains of EAV and
the ARVAC vaccine virus. Dots indicate the same amino acid as in the top aligned sequence. The variable region (V1) and constant regions (C1
and C2) are indicated above the sequences. The two predicted glycosylation sites are underlined. Deleted amino acids are indicated by ‘‘ˆ’’. (a)
Critical amino acid substitutions in EMs are indicated by bold letters as compared to the EAVUCD virus. (b) Significant amino acid substitutions
that are at similar locations in the neutralization-resistant variants as well as the field isolates of EAV are indicated in bold letters. CA95I*, DL8**,
and DL11** isolates from semen are included for comparison (*Balasuriya et al., 1997b; **Glaser et al., 1995).
mational epitopes recognized by MAbs 1H7, 1H9, and recognized by MAb 1H9, which includes amino acids 69
and 99 to 102.6A2; nonconformational epitopes recognized by MAbs
2B3, 5F8, and 8D4). The nucleotide substitution at position 11,309 of DEM
5E8. 22 resulted in a lysine to glutamic acid change atThe DEM 1H7. 13 had a nucleotide change at position
11,279 which resulted in an amino acid substitution at position 61 of the GL protein. DEM 5E8. 22 escapes neutral-
ization by MAb 1H9, indicating that amino acid 61 is integralposition 49 (aspartic acid to asparagine) and it was neu-
tralized by all the MAbs raised to EM6D10 except MAb to the neutralization epitope recognized by MAb 1H9.
The histidine at position 99 of EM 6D10 was changed1H9. With the exception of DEMs 2B3. 20 and 2B3. 25
all the other DEMs were neutralized to variable titers to valine (DEM 2B3. 25), leucine (DEM 2B3. 20, 8D4. 18,
and 10B4. 9), or proline (DEM 5F8.6), and these single(200–6400) by MAb 1H7. These data suggest that the
epitope recognized by MAb 1H7 is independent but ex- substitutions were responsible for the altered neutraliza-
tion phenotype of these viruses. With the sole exceptionerts some indirect conformational effect on the epitope
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of DEM 10B4. 9 these viruses were completely resistant the fact that these viruses are infectious and neutralized
by MAb 1H7 and polyclonal equine antisera indicatesto neutralization by MAb 10H4. DEM 10B4. 9, which had
the same amino acid substitution as EM viruses 2B3. 20 that other neutralization sites must exist on the GL pro-
tein.and 8D4. 18, was neutralized to a lower titer (1600) by
MAb 10H4 as compared to the control virus (X2. 4; The control virus X2.4 (derived from parent virus
EM6D10) had a single amino acid substitution at position12,800). However, DEM 10B4.3 (another escape mutant
to MAb 10B4) which lacked amino acids 100 and 101 113, which had no apparent effect on the neutralization
phenotype of this virus. In a previous study, Glaser et al.escaped neutralization by MAb 10H4, indicating that the
epitope recognized by MAb 10B4 is centered on the re- (1995) suggested that amino acids 99 and 100 are critical
for virus neutralization and that amino acids 96 and 113gion of amino acids 99 to 101 or that amino acid substitu-
tions in this region may have a conformational effect might also contribute to the neutralization resistance of
EM viruses. However, in our studies with a large panelon a distant site which may be deleted in DEM 10B4.3.
Furthermore, DEM 7C5. 17, which had an amino acid of neutralization resistant viruses, field isolates and the
ARVAC vaccine virus, we did not detect any changes insubstitution at position 102 also escaped neutralization
by MAb 10H4 which identifies an epitope at amino acids either amino acid 96 or 113 that clearly affected virus
neutralization. Similarly, the glycine to serine substitution102 and 103 (Balasuriya et al., 1995a). Results of this
study indicate that this epitope also can be affected by at position 113 of the control virus did not affect the
neutralization phenotype of the virus.the amino acid at position 99, and these data further
emphasize that amino acids 99 through 104 contain mul-
tiple interacting epitopes that are critical for neutraliza- Amino acid changes in the GL protein of field strains
tion of EAV. The MAbs 2B3, 5F8, 8D4, and 10B4 also and the vaccine strain of EAV and their possible
failed to neutralize or immunoblot EAVUCD and EAV- effect on neutralization phenotype
CVDLS (Table 3; representative example in Fig. 1, lane
8). The EM6D10 was derived from EAVUCD (Balasuriya The amino acid substitutions in the GL protein of neu-
tralization resistant variants of EAVUCD (EM 5G11, 6D10,et al., 1995a) and has a single amino acid substitution
at position 99, which may have changed the major neu- 7E5, 10H4, and DEM 6D10/10H4; Balasuriya et al., 1995a)
and the DEMs in this study were compared to the aminotralization site of the GL protein and/or may have altered
the conformation of this region. The MAbs raised against acid sequences of the GL protein of 19 field strains, four
laboratory strains (EAVUtr, EAVATCC, EAVCVDLS, andEM 6D10 are produced to this ‘‘altered’’ neutralization
site, which likely explains why they do not effectively EAVUCD) and the ARVAC vaccine virus. Amino acid sub-
stitutions in the GL protein of these viruses, as comparedneutralize the original virus. Furthermore the four MAbs
(2B3, 5F8, 8D4, and 10B4) which identified a common to EAVUtr, are shown in Fig. 2. With the exception of
VBS53 and PLD76, the field isolates had multiple substi-linear epitope at position 99 selected neutralization vari-
ants with different amino acid substitutions at this posi- tutions in the region of amino acids 67 through 90. Some
of the amino acid substitutions in the field isolates andtion.
The ORF5 of DEM 3F4. 8 was 141 nucleotides (11,324 – the vaccine virus were identical to those of individual
neutralization resistant viruses [e.g., position 49 arginine11,464; Table 4) shorter than that of the parent virus EM
6D10. Due to this 141 contiguous nucleotide deletion, in IL93TB; position 61 glutamic acid in KY93, MI93,
IL93AB, IL93TB, CAN86, and CA95G; position 69 prolinethe GL protein of DEM 3F4. 8 was 47 amino acids (66 –
112; Figs. 2 and 3) shorter than that of EM 6D10 and in PLD76 and ARVAC vaccine virus (Figs. 2 and 3)]. In
addition, some of the field isolates had different aminoEAVUCD (206 amino acids instead of 253 amino acids).
Similarly, the sequence of ORF5 of DEM 10B4. 3 was acid substitutions at the same residue as the EM viruses
(e.g., position 61 glutamine and aspartic acid in KY84120 nucleotides (11,318– 11,437) shorter than that of the
parent virus EM 6D10. Due to this 120 contiguous nucleo- and NE88; position 104 glycine in ARVAC vaccine and
PLD76, and asparagine in KY93, MI93, IL93AB, andtide deletion, the GL protein of DEM 10B4. 3 was 40
amino acids (62–101; Figs. 2 and 3) shorter than that of SWZ64). With the exception of PLD76 and KY63, and the
ARVAC vaccine, the nonlaboratory strains of EAV (fieldthe EM 6D10 and EAVUCD (213 amino acids). The amino
acid deletion from residues 66–101 (36 amino acids) was strains) all had a second glycosylation site at position
81 of the GL protein. All eight cysteine residues (3 in thecommon to both deletion mutants. With the exception of
MAb 1H7, which recognizes an epitope centered on V1 region) were preserved in the GL protein of the field
isolates, indicating that these are highly conserved.amino acid 49, both of these deleted viruses were not
neutralized by any of the MAbs or polyclonal rabbit anti- The neutralization phenotype of each EAV field isolate
was determined by microneutralization assay using theEAV serum, indicating that they both lack a critical neu-
tralization region of the GL protein. This data further con- 17 MAbs to EAVUCD and EM6D10, as well as rabbit and
equine polyclonal anti-EAV serum (Table 3). The SWZ64,firms the significance of amino acids 66 to 101 to the
major neutralization site identified by the MAbs; however, PLD76, KY77, CAN86, MT89, MI93, IL93AB, CA95, and
AID VY 8551 / 6a36$$$103 05-05-97 16:01:07 vira AP: Virology
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FIG. 3. Proposed neutralization sites (A, B, C, and D) in the amino-terminal ectodomain of the GL envelope glycoprotein of EAV. Critical amino
acids substitutions on the GL protein of EM viruses, field isolates, and the vaccine virus are indicated in the figure. Deleted amino acids are
indicated by the hatched boxes. *The fusion protein and synthetic peptide described by Chirnside et al. (1995). **The synthetic peptide previously
described by Balasuriya et al. (1995a).
ARVAC vaccine viruses were not neutralized by any of and to generally low titers (32 to 1024) by MAbs raised
to EAVUCD. The vaccine virus was neutralized to similarthe MAbs raised to EM6D10 (Table 3), whereas all the
other field isolates were neutralized by the MAb 6A2 to titers as was PLD76 but they significantly differed in their
neutralization by MAbs 5G11, 6D10, and 10H4.variable titers (64 to 512). PA76 was neutralized by all
MAbs raised to EM6D10 to a titer of 64 to 128. MAb There were six amino acid substitutions in the V1 re-
gion of the vaccine virus (Fig. 2; positions 69, 72, 100,1H7 neutralized VBS53 to a titer of 128, and MAb 8D4
neutralized KY84 and ITA92 to a similar titer. 101, 104, and 106). Similar changes have been previously
reported by Glaser et al. (1995). Interestingly, the aminoThe MAbs to EAVUCD neutralized most of the field
isolates of EAV to a titer of ⁄64; however, some viruses acid substitution at positions 69 was similar to that pres-
ent in some of the EM viruses. The vaccine virus alsohad significantly lower neutralization titers as compared
to the EAVUCD prototype (Table 3). For instance, the lacked the second glycosylation site at position 81.
These findings indicate that the major neutralization re-neutralization titer of PLD76 varied from 32 to 1024 as
compared to 2048 to 4096 for the prototype. Similarly, gion of the ARVAC vaccine virus is significantly different
from that of other field isolates, which is reflected in itsthe AZ87 and vaccine viruses were generally neutralized
to lower titer than the prototype. The data indicate that generally weak neutralization by the MAbs in our panel
(Table 3). Despite this variation, the ARVAC vaccine hasthere are significant antigenic differences among these
viruses, with PA76 and PLD76 representing opposite ex- successfully protected horses against clinical EVA (Timo-
ney and McCollum, 1993). It is also appreciated that thetremes. PA76 was neutralized by all the 17 MAbs to a
titer of ⁄64 (highest titer 4096), whereas PLD76 was epitopes recognized by murine MAbs may differ from
those recognized by the horse.not neutralized by any of the MAbs raised to EM6D10
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TABLE 4
Nucleotide and Deduced Amino Acid Changes in the ORF5 Region of Neutralization: Resistant Viral Variantsa
Nucleotide substitutions Amino acid substitutions
Virus Position nt change Codon change Position aa change
EM 6D10 11,423 T r C TAC r CAC 99 Tyr r Hisb
DEM 1H7.13 11,279 G r A GAT r AAT 49 Asp r Asnc
11,423 T r C TAC r CAC 99 Tyr r Hisb
DEM 1H9.7 11,334 T r C CTG r CCG 69 Leu r Pro
11,423 T r C TAC r CAC 99 Tyr r Hisb
DEM 2B3.20 11,371 T r C GAT r GAC 81 No change
11,423 T r C TAC r CTC 99 Tyr r Leud
11,424 A r T [His r Leu]e,f
DEM 2B3.25 11,423 T r G TAC r GTC 99 Tyr r Vald
11,424 A r T [His r Val]e,f
DEM 3F4.8 11,324– 11,464 141 contiguous nt’s 47 codons are deleted 66–112 47 amino acids are
are deleted deleted
DEM 5E8.22 11,309 A r G AAA r GAA 61 Lys r Glug
11,423 T r C TAC r CAC 99 Tyr r Hisb
DEM 5F8.6 11,423 T r C TAC r CCC 99 Tyr r Prod
11,424 A r C [His r Pro]e,f
DEM 6A2.12 11,334 T r C CTG r CCG 69 Leu r Pro
11,423 T r C TAC r CAC 99 Tyr r Hisb
DEM 7C5.17 11,423 T r C TAC r CAC 99 Tyr r Hisb
11,433 T r A CTG r CAG 102 Leu r Gln
11,449 C r T CCC r CCT 107 No change
DEM 7D4.30 11,334 T r C CTG r CCG 69 Leu r Pro
11,423 T r C TAC r CAC 99 Tyr r Hisb
DEM 8D4.18 11,423 T r C TAC r CTC 99 Tyr r Leud
11,424 A r T [His r Leu]e,f
DEM 10B4.3 11,318– 11,437 120 contiguous nt’s 40 codons are deleted 62–101 40 amnio acids are
are deleted deleted
DEM 10B4.9 11,423 T r C TAC r CTC 99 Tyr r Leud
11,424 A r T [His r Leu]e,f
11,848 C r T AGC r AGT 240 No change
Control X2.4 11,423 T r C TAC r CAC 99 Tyr r Hisb
11,465 G r A GGC r AGC 113 Gly r Ser h
Note. Both the nucleotide and the amino acid sequences of DEMs are numbered according to the published sequence of EAVUtr (den Boon et
al., 1991) for consistency. Significant amino acid changes are indicated by superscripts.
a As compared to the ORF5 sequence of EAVUCD parent virus (Balasuriya et al., 1995a).
b Uncharged polar amino acid to a basic amino acid.
c Acidic amino acid to a uncharged polar amino acid.
d Uncharged polar amino acid to a nonpolar amino acid.
e As compared to the ORF5 sequence of EM 6D10 virus (Balasuriya et al., 1995a).
f Basic amino acid to a nonpolar amino acid.
g Basic amino acid to a acidic amino acid.
h Nonpolar amino acid to uncharged polar amino acid.
The neutralization of viruses isolated from the same the semen of a persistently infected stallion in California,
indicated that this virus is antigenically distinct fromgeographic area sometimes varied, thus North American
and European isolates were neutralized by individual some of the other field isolates of EAV. For instance the
CAN86 virus, which was genetically related to CA95GMAbs to different titers. Similarly, some of the isolates
made in the same year (e.g., 1993 isolates) varied from (Balasuriya et al., 1997b), had a different neutralization
phenotype but had only two amino acid (positions 73 andeach other. The IL93TB and IL93AB viruses, for example,
had different amino acid substitutions (Fig. 2; position 82) differences in the V1 region.
104 in IL93AB and position 49 in IL93TB) and also had
distinct neutralization phenotypes (Table 3). The viruses DISCUSSION
also were neutralized by the polyclonal equine anti-EAV
sera to variable titers (32 to 512). The phenotypic charac- The objective of this study was to further characterize
the neutralization determinants of EAV using neutralizingterization of the CA95G virus, which was isolated from
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MAbs, neutralization-resistant EM viruses, and field et al. (1994) demonstrated that a neutralizing MAb bound
the GL protein after much of the carboxy terminal portionstrains of EAV from North America and Europe. All neu-
tralizing MAbs in our panel bind linear or conformational (amino acids 116–211) was deleted, and we established
that mice inoculated with a synthetic peptide that in-neutralization determinants on the GL envelope glycopro-
tein. Sequence analysis of the DEM viruses localized cluded amino acids 93–112 of the GL protein developed
neutralizing antibodies (Balasuriya et al., 1995a). The N-all mutations and deletions responsible for their altered
phenotype to a span of 186 nucleotides (11,279–11,464) terminal ectodomain of the GL protein of EAV clearly con-
tains major neutralizing determinants recognized by im-in ORF5, and 64 amino acids (49 to 112) in the GL protein.
Substitutions of single amino acids at residues 49, 61, 69, mune sera from horses, rabbits, and mice, and most but
not all of these determinants are located in the V1 region.99, and 102 of the GL protein clearly confer neutralization
resistance to individual EM viruses, which is consistent The panel of neutralizing MAbs identified significant anti-
genic variation among field isolates of EAV from Northwith results of a previous study in which we identified
three interactive neutralization epitopes that included America (e.g., PA76, KY63, IL93AB, and IL93TB) and Europe
(e.g., AUT68, PLD76, ITA92, and SWZ64). The neutralizationamino acids 99–104 of the GL protein (Balasuriya et al.,
1995a). In another study, Glaser et al. (1995) also con- phenotype of AZ87 is significantly different from that of
all other isolates of EAV from North America and Europe,cluded that amino acids 99 and 100 of the GL protein
constituted a major neutralization site of EAV. Data ob- although it is ancestrally related to the European viruses
and was introduced into the United States by a persistentlytained with the EM viruses indicate that amino acids 99–
104 of the GL protein constitute a critical neutralization infected stallions imported from eastern Europe (Balasuriya
et al., 1995b). The data also indicate that there is antigenicsite of EAV, and that other regions of the GL protein (e.g.,
amino acids 49, 61, and 69) likely exert a conformational variation among virus isolates derived from the same geo-
graphic area, as well as among isolates from the sameinfluence on this site. With the notable exception of
amino acid 49 [located in the C1 region (amino acids 19– year or even the same outbreak of EVA. Some amino acid
substitutions in the EM viruses also were present in field60)], all other amino acid substitutions critical to neutral-
ization resistance were localized to the V1 variable region isolates (Figs. 2 and 3), which is consistent with the variable
neutralization of field strains of EAV by individual MAbs.of the GL protein.
The GL protein may function as both a receptor binding With the sole exception of IL93TB, most of the critical amino
acid substitutions in the GL protein of field isolates wereand membrane fusion protein (de Vries, 1994; de Vries
et al., 1992). The two deletion mutants (DEM 3F4. 8 and clustered in the V1 region (Fig. 2) and the incidence of
critical amino acid substitutions (e.g., at positions 61, 69,10B4. 3 that, respectively, lack amino acids 66–112 and
62–101) retained their ability to infect cells and to pro- 99, and 104) in field isolates would appear to have markedly
increased since 1984. The major difference between theduce infectious progeny virus, which indicates that an-
other receptor binding region of EAV may be located EM viruses (with the exception of the two deletion mutants)
and field isolates is that none of the amino acid substitu-distant to amino acids 62 –112 of the N-terminal hydro-
philic ectodomain of the GL protein, possibly between tions in the EM viruses occur between amino acids 71 and
90, whereas a large number of amino acids substitutionsamino acids 19 and 61. With the notable exception of
MAb 1H7 (which is specific for amino acid 49), the two are present in this region of the GL protein of the field
isolates. The altered neutralization phenotype of the fielddeletion mutants were not neutralized by any of the MAbs
or by the polyclonal rabbit antisera, indicating that the isolates of EAV strongly suggests that amino acids 71–90
either directly or indirectly influence other neutralizationdeleted portion of the GL protein includes the neutraliza-
tion determinants recognized by rabbit antisera and all sites, which is consistent with data obtained with an immu-
nogenic peptide (Chirnside et al., 1995). Comparative analy-but one of the neutralizing MAbs. The deleted EM viruses
were neutralized by equine anti-EAV serum, although the sis of data obtained from the various field isolates and EM
variants of EAV indicates that there are at least four poten-titers were low with some sera (Table 2), thus immune
horse sera must recognize additional neutralizing epi- tial neutralization sites on the GL protein of EAV (Fig. 3),
including amino acids 49 (site A), 61 (site B), 67–90 (sitetopes that are not included in the deleted region. We
previously have shown, however, that equine antisera to C), and 99–106 (site D).
All the field isolates of EAV, except KY63 and PLD76,EAV competitively inhibits the binding of neutralizing
MAbs specific for amino acids 99–104 of the GL protein had a second glycosylation site at position 81, whereas
the extensively cell culture passaged laboratory strainsof EAV (Balasuriya et al., 1993), thus this region also
contains neutralization determinants of EAV recognized [EAVUCD, EAVCVDLS, EAV-NVSL (Glaser et al., 1995),
and EAVUtr (den Boon et al., 1991)] and the ARVAC vac-by infected horses. Furthermore, Chirnside et al. (1995)
reported that horses developed neutralizing antibodies cine virus (Wilson et al., 1962; McCollum et al., 1961,
1962) all lacked this site. Interestingly, the VBS53 andafter they were inoculated with either a fusion protein
that included amino acids 55–98 of the GL protein or a ATCC strains of EAV have the second glycosylation site,
whereas the laboratory strains do not, despite the factsynthetic peptide of amino acids 75–97. Similarly, Deregt
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that all these viruses ultimately were derived from the moving the new virus to a new fitness peak. In this cross-
ing it may be advantageous for the variant to take aoriginal Bucyrus strain of EAV. The EAVUCD, EAVCVDLS,
and KY63 viruses, all of which lack the second glycosyla- longer route (consisting of more mutations) if that en-
ables it to avoid a particularly deleterious mutation. Thetion site, had consistently high neutralization titers with
the panel of MAbs raised against EAVUCD, as compared appearance of multiple amino acids substitutions in the
V1 region of the field strains of EAV, particularly in theto the PLD 76 and vaccine viruses, which also lack this
site but were weakly neutralized by the same MAbs (spe- region of amino acid 67–90 (site C) of different EAV
strains, strongly suggests that these viruses are takingcifically with MAbs 7E5 and 9F2). The former three vi-
ruses (EAVUCD, EAVCVDLS, and KY63) also had the a longer route in order to generate stable variants with
an altered phenotype. Interestingly, changes in this re-least variation in neutralization sites A, B, and C as com-
pared to EAVUtr, whereas, PLD 76 and ARVAC had amino gion were also consistently present in viruses isolated
from the semen of persistently infected stallions (Bal-acid substitutions at critical positions (amino acids 69,
101, and 104) in the C and D neutralization sites (Figs. asuriya et al., 1997b; Glaser et al., 1995). The effects of
substitutions in the region of amino acids 67–90 on the2 and 3). Furthermore, some viruses with the second
glycosylation site were neutralized to high titer by the phenotypic variation of EAV, and the apparent increased
incidence of clinical EVA since 1984 (Timoney andMAbs despite significant amino acid changes in sites B,
C, and D (e.g., KY84, NE88, MI93). Divergent neutraliza- McCollum, 1987, 1988, 1993; Timoney, 1992; Timoney et
al., 1992), clearly warrants further investigation.tion phenotype, therefore, likely is dependent not only on
the extent of glycosylation of the GL protein, but also In summary, comparative nucleotide and amino acid
analyses of neutralization resistant variant viruses, ason the conformational influence of amino acids in other
portions of the GL protein. well as field and laboratory strains of EAV, indicate that
there are mutational ‘‘hot spots’’ that are noncontiguousThe high number of nonsynonymous amino acid sub-
stitutions in the V1 region, particularly in the region of within the N-terminal ectodomain of the GL protein. We
have identified four neutralization sites on the GL proteinamino acids 67–90 (site C), coupled with the presence
of a second N-glycosylation site, may provide a selective (Fig. 3), which include amino acids 49 (site A), 61 (site
B), 67 through 90 (site C), and 99 through 106 (site D).advantage to mutant viruses. Amino acids in the four
neutralization sites (A, B, C, and D) either form linear With the notable exception of site A, all of these sites
are located in the V1 variable region within the N-terminalneutralization sites (epitopes) or are crucial for the ter-
tiary folding of the GL protein and so contribute to nonlin- hydrophilic ectodomain of the GL protein. The site D ex-
presses several overlapping linear epitopes (Balasuriyaear conformational epitopes within the envelope glyco-
protein. Alterations in the neutralization determinants of et al., 1995a; Glaser et al., 1995) in the GL protein, and
it may interact with the other three sites to form a large 3-individual strains of EAV could reflect an adaptive re-
sponse of the virus to avoid host immune responses. dimensional (conformationally dependent) neutralization
domain. Further studies will be required to determineAntibodies clearly can drive the selection of variant vi-
ruses; however, the extent of other selective forces, such whether immune selection of individual members of the
virus quasispecies plays a critical role in evolution ofas cell type and tissue tropism in influencing the fixation
of amino acid substitutions within the GL protein during EAV, persistent infection of stallions, as well as the peri-
odic emergence of virulent strains of this virus amongthe evolution of EAV is not clear.
Our studies have demonstrated that variation within endemically infected populations of horses.
the V1 region of the GL protein accompanies and likely
facilitates adaptation and evolution of EAV (Balasuriya et ACKNOWLEDGMENT
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